Skip to Content

Firmagon (degarelix) Disease Interactions

There are 3 disease interactions with Firmagon (degarelix):


Degarelix (applies to Firmagon) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Hepatic impairment can lower degarelix exposure. It is recommended to monitor testosterone concentrations on a monthly basis in patients with hepatic impairment until medical castration is achieved. Degarelix has not been studied in patients with severe hepatic impairment and caution is therefore warranted in this group of patients.


Degarelix (applies to Firmagon) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Data on patients with moderate or severe renal impairment is limited and therefore degarelix should be used with caution in patients with CrCl < 50 mL/min.


GNRH antagonists (applies to Firmagon) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome, Congestive Heart Failure, Electrolyte Abnormalities

Androgen deprivation therapy may prolong the QT/QTc interval. Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval. Consider periodic monitoring of EKG and electrolytes.

Firmagon (degarelix) drug interactions

There are 216 drug interactions with Firmagon (degarelix)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.